Sales and Marketing

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) have approved a change to

LEO Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis

https://pharmaphorum.com/news/leo-pharmas-adtralza-approved-by-mhra-ec-for-adolescent-atopic-dermatitis/

News/ News/ Sales and Marketing

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

Phil Taylor Grunenthal, Kyowa Kirin, M&A, pain, Sales and Marketing 0 Comment

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

https://pharmaphorum.com/news/grunenthal-buys-into-kyowa-kirins-mature-medicines-portfolio/

News/ News/ News/ R&D/ Sales and Marketing

J&J builds case for antidepressant Spravato with head-to-head trial

Phil Taylor depression, Janssen, Johnson & Johnson, Psychiatry, Spravato 0 Comment

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in

J&J builds case for antidepressant Spravato with head-to-head trial

https://pharmaphorum.com/news/jj-builds-case-for-antidepressant-spravato-with-head-to-head-trial/

Events/ Insights/ Reuters Pharma 2022/ Sales and Marketing/ Views and analysis

A Reuters Pharma conversation with EY: smart reviewing and payment outcomes

Nicole Raleigh AI, data, EY Consulting, health outcomes, machine learning, patient centricity, payment outcomes, pharma, Reuters Pharma, Smart Reviewer 0 Comment

Harking back to the Reuters Pharma 2022 event, held at the Nice Acropolis convention centre on France’s South

A Reuters Pharma conversation with EY: smart reviewing and payment outcomes

https://pharmaphorum.com/views-and-analysis/a-reuters-pharma-conversation-with-ey-smart-reviewing-and-payment-outcomes/

Market Access/ News/ News/ News/ Sales and Marketing

uniQure, CSL claim first okay for haemophilia B gene therapy

Phil Taylor CSL, gene therapy, Haematology, haemophilia, haemophilia B, Hemgenix, regulatory approval, uniQure 0 Comment

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for

uniQure, CSL claim first okay for haemophilia B gene therapy

https://pharmaphorum.com/news/uniqure-csl-claim-first-okay-for-a-haemophilia-b-gene-therapy/

News/ News/ News/ Oncology/ Sales and Marketing

GSK will pull Blenrep from US market after failed trial

Phil Taylor Blenrep, GlaxoSmithKline, multiple myeloma, Oncology, regulatory, Sales and Marketing 0 Comment

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported

GSK will pull Blenrep from US market after failed trial

https://pharmaphorum.com/news/gsk-will-pull-blenrep-from-us-market-after-failed-trial/

Appointments/ News/ News/ Sales and Marketing

Teva names ex-Sandoz exec Richard Francis to replace CEO Schultz

Phil Taylor appointment, senior management, Teva 0 Comment

Israeli drugmaker Teva has appointed former Sandoz and Biogen executive Richard Francis to succeed current CEO Kare Schultz,

Teva names ex-Sandoz exec Richard Francis to replace CEO Schultz

https://pharmaphorum.com/news/teva-names-ex-sandoz-exec-richard-francis-to-replace-ceo-schultz/

Digital/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Elon Musk, pharma, and the future of Twitter

Ben Hargreaves advertising, Eli Lilly, Elon Musk, HCPs, healthcare, pharma, social media, Twitter 0 Comment

Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter

Elon Musk, pharma, and the future of Twitter

https://pharmaphorum.com/views-and-analysis/elon-musk-pharma-and-the-future-of-twitter/

News/ News/ Sales and Marketing

Provention prices type 1 diabetes drug Tzield at $194,000

Phil Taylor Diabetes, Drug pricing, Provention Bio, Sales and Marketing, type 1 diabetes, Tzield 0 Comment

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial –

Provention prices type 1 diabetes drug Tzield at $194,000

https://pharmaphorum.com/news/provention-prices-type-1-diabetes-drug-tzield-at-194000/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Sales and Marketing

Login